Trial Profile
A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs BV NSCLC 001 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2023 Planned number of patients changed from 193 to 242.
- 06 Nov 2023 Planned End Date changed from 9 Dec 2023 to 9 Dec 2027.
- 06 Nov 2023 Planned primary completion date changed from 9 Dec 2023 to 9 Dec 2027.